Q-Med year-end report 2009
(Thomson Reuters ONE) - PRESS RELEASEUppsalaFebruary 2, 2010Q-Med AB invites to year-end report 2009 conference callTime:                                    Friday, February 12 at 10.30 a.m. CET.To join the conference:   Swedish dial in number: +46 8 5052 0114                                               UK dial in number: +44207 1620 177Q-Med participants:          Bengt ?erup, CEO                                               Alexander Kotsinas, CFOQ-Med AB's year-end report will be released 8.00 a.m. on February 12, 2010.The slide presentation will be available at www.q-med.com and Investors/Presentations.A recorded version of the presentation will be available for seven working daysontel: Sweden +46 8 505 203 33 or UK +44 20 7031 4064, access code: 857246Financial information from Q-Med during 201012 February      Year-end Report 200923 April            Interim Report January - March 201028  April             Annual General Meeting22  July               Interim Report January - June 201022  October       Interim Report January - September 2010Queries should be addressed to:Camilla Schartau, IR Co-ordinatorTel: +46 733 87 14 22Q-Med AB is a medical device company. The company develops, manufactures,markets, and sells primarily medical implants. The majority of the products arebased on the company's patented technology, NASHA(TM), for the production ofstabilized non-animal hyaluronic acid. The product portfolio today contains:Restylane® for filling lines and folds, contouring and creating volume in theface, Macrolane(TM) for body contouring, Durolane(TM) for the treatment ofosteoarthritis of the hip and knee joints, Deflux® for the treatment ofvesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children,and Solesta(TM) for the treatment of fecal incontinence. Sales are made throughthe company's own subsidiaries or distributors in over 70 countries. Q?Med todayhas about 650 coworkers, with approximately 400 at the company's head office andproduction facility in Uppsala, Sweden.Q-Med AB is listed in the Mid Cap segment of the NASDAQ OMX Nordic. Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate identity number 556258-6882. Tel: +46 18 474 90 00. Fax: +46 18 474 90 01. E-mail: info(at)q-med.com . Web: www.q-med.com .[HUG#1379758] Invitation pdf: http://hugin.info/130306/R/1379758/339655.pdf
Weitere Infos zu dieser Pressemeldung:Unternehmensinformation / Kurzprofil:Bereitgestellt von Benutzer: hugin
Datum: 03.02.2010 - 09:02 Uhr
Sprache: Deutsch
News-ID 12015
Anzahl Zeichen: 0
contact information:
Town:
Kategorie:
Diese Pressemitteilung wurde bisher
170 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"
Q-Med year-end report 2009"
steht unter der journalistisch-redaktionellen Verantwortung von
Q-Med AB
(
Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum
Haftungsauschluß (gemäß
TMG - TeleMedianGesetz) und dem
Datenschutz (gemäß der
DSGVO).
